文献速递白血病造血干细胞移植与细胞治疗

Obecabtagene autoleucel 对比外部对照臂治疗成人复发/难治性B细胞急性淋巴细胞白血病

Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
PubMed 文献 · Leukemia · 2026-07-17

基于单臂Ib/II期FELIX研究(n=107),采用倾向性评分匹配历史对照比较obe-cel与非CAR-T标准治疗(贝林妥欧单抗、奥加伊妥珠单抗、化疗)的疗效与安全性。Obe-cel的总体缓解率显著更高(67.3% vs 51.4%),无事件生存期和总生存期均更优,安全性相当。

要点

  • Obe-cel组总体缓解率67.3%,显著高于非CAR-T标准治疗的51.4%。
  • Obe-cel组中位无事件生存期9.8个月,显著优于对照组的2.5个月。
  • 两组≥3级不良事件发生率相似,安全性特征相当。

核心结论

  • Obe-cel较当前非CAR-T标准治疗在成人复发/难治性B-ALL中提供更高的缓解率和生存获益,且安全性可接受。

研究设计与样本

  • 单臂Ib/II期FELIX研究(NCT04404660)的意向治疗人群(n=107)与倾向性评分匹配的历史外部对照臂进行比较。
  • 外部对照臂代表非CAR-T标准治疗:贝林妥欧单抗、奥加伊妥珠单抗和传统化疗。

主要发现

  • Obe-cel组总体缓解率为67.3%,非CAR-T治疗组为51.4%(比值比1.9;p=0.0257)。
  • Obe-cel组中位总生存期在删失造血干细胞移植后为15.1个月 vs 7.0个月(p=0.0015),未删失时为13.9个月 vs 7.8个月(p=0.0430)。
  • Obe-cel组中位无事件生存期为9.8个月 vs 2.5个月(p<0.0001)。
  • 两组≥3级不良事件发生率相似,安全性特征相当。

临床怎么用

  • 对于成人复发/难治性B-ALL,obe-cel可作为优于非CAR-T标准治疗的候选方案,尤其适用于需要提高缓解率和生存获益的患者。

局限性

  • 比较基于单臂研究与非随机历史对照的倾向性评分匹配,可能存在未测量混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the single-arm Phase Ib/II FELIX study (NCT04404660), obecabtagene autoleucel (obe-cel; CD19-directed autologous CAR T-cell therapy) demonstrated high overall remission rates (ORR) and a favorable safety profile in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). To contextualize results from FELIX, we compared the efficacy and safety of obe-cel with matched external control arms (ECA) derived from historical trials using propensity score matching. ECAs represented standard of care (SoC) non-CAR T-cell therapies: blinatumomab, inotuzumab ozogamicin, and conventional chemotherapy. The primary endpoint was ORR; secondary endpoints included overall survival (OS). Event-free survival (EFS) and safety were exploratory endpoints. Among the intent-to-treat population in FELIX (n = 107), obe-cel demonstrated significantly higher ORR than non-CAR T-cell therapies (67.3% vs 51.4%; odds ratio 1.9; p = 0.0257). Median OS was longer with obe-cel when censoring for hematopoietic stem cell transplant (15.1 vs 7.0 months; p = 0.0015) and without censoring (13.9 vs 7.8 months; p = 0.0430). EFS was significantly improved with obe-cel (median 9.8 vs 2.5 months; p < 0.0001). Safety profiles were comparable between groups, with similar rates of Grade ≥3 adverse events. Obe-cel offers superior remission rates and survival benefits over current SoC non-CAR T-cell therapies, with an acceptable safety profile; its use could address unmet needs in adult R/R B-ALL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Topp MS, Shah BD, Jabbour E, et al. Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Leukemia. 2026. PMID: 42469475. doi:10.1038/s41375-026-03045-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。